GHRP 6 (5mg x 10 Vials) and CJC 1295 DAC (5mg x 10 Vials)

GHRP-6 & CJC-1295 DAC Peptide Combination

Research peptides / unlicensed medicinal products

Growth hormone\u2013releasing peptide and GHRH analogue peptide combination (lyophilised vials)

No MHRA marketing authorisation identified for this combined product as a medicinal product in the UK.
No specific CE marking as a medical device could be confirmed for this peptide bundle.
Sold in the category of research chemicals/peptides, which typically fall outside the scope of licensed medicines regulation when marketed strictly for laboratory use.

No MHRA marketing authorisation identified for this combined product as a medicinal product in the UK.
No specific CE marking as a medical device could be confirmed for this peptide bundle.
Sold in the category of research chemicals/peptides, which typically fall outside the scope of licensed medicines regulation when marketed strictly for laboratory use.

Growth hormone\u2013releasing peptide and GHRH analogue peptide combination (lyophilised vials)

Description

This product is a peptide combination bundle consisting of GHRP-6 and CJC-1295 DAC supplied as lyophilised powders in separate vials. Each bundle contains 10 vials of GHRP-6 (5 mg per vial) and 10 vials of CJC-1295 DAC (5 mg per vial). The product is marketed as a research peptide combination and is typically labelled for laboratory or research use only, not for human or veterinary administration.

Bnefits

Provides separate, pre-weighed lyophilised vials of GHRP-6 and CJC-1295 DAC intended for research applications.
Standard 5 mg per vial presentation for each peptide simplifies calculation of concentrations in experimental settings.
Bundle format (10 vials of each peptide) facilitates multi-sample or repeated experimental use.
Supplied as a dry (freeze-dried) powder to support stability during shipment and storage before reconstitution.
Commonly used in pre-clinical and in vitro research exploring growth hormone–related signalling pathways (not for clinical or human use).

Indications

Sold and labelled as research peptides for laboratory investigation only.
Not indicated as a licensed treatment for any human or veterinary medical condition.
Any clinical or performance-enhancement use would be outside authorised medicinal frameworks and may be unsafe or illegal.

Composition

GHRP-6 peptide (Growth Hormone Releasing Peptide-6) – 5 mg per lyophilised vial (10 vials in the bundle).
CJC-1295 DAC peptide (growth hormone–releasing hormone analogue with Drug Affinity Complex) – 5 mg per lyophilised vial (10 vials in the bundle).
Lyophilised (freeze-dried) peptide powder in sterile vials; specific excipients, if any (e.g. mannitol, buffering agents), are not detailed in the public product listing.

Formulation

Lyophilised peptide powders supplied in sterile glass vials.
Each GHRP-6 vial contains 5 mg of peptide in dry form.
Each CJC-1295 DAC vial contains 5 mg of peptide in dry form.
Intended to be reconstituted with a suitable sterile diluent in research environments according to institutional protocols (not for injection into humans or animals).

Packaging

10 x 5 mg vials of GHRP-6 lyophilised peptide.
10 x 5 mg vials of CJC-1295 DAC lyophilised peptide.
Total of 20 vials supplied as a combination bundle.
Vials packaged in protective outer packaging suitable for shipment; detailed inner packaging configuration is not specified in the public listing.
Typically labelled for research use only / not for human consumption (based on standard industry practice for such products).

Usage

Product is intended for laboratory research use only and is not approved for human or veterinary administration.
Handling, storage, reconstitution and disposal should follow institutional guidelines for research chemicals and peptides.
Do not self-administer or use clinically; there is no validated dosing, safety or quality assurance for medicinal use in humans.
Researchers should consult their own institutional protocols and safety data before working with peptide powders.
Any further instructions regarding reconstitution volumes or handling should be taken from the product label or documentation provided directly by the supplier, if available.

Contraindications

Not for human or veterinary use; self-administration or non-research use is contraindicated and may be unsafe.
Should not be used as a substitute for licensed medicines or under unsupervised conditions.
Individuals with any medical condition or taking other medications should not use this product outside of formal, regulated research frameworks.
Contraindicated for use by pregnant or breastfeeding individuals, minors or anyone outside a controlled research setting.

Adverse Effects

No formal safety profile is established for this specific commercial product in humans, as it is sold for research use only.
Use outside research settings (e.g. self-injection) may pose serious, unpredictable risks including endocrine disruption, cardiovascular strain, metabolic effects and local injection reactions or infection.
Illicit or unregulated peptide products may be mislabelled, contaminated or inaccurately dosed, increasing the risk of harm.

Storage Conditions

Store in a cool, dry place according to any temperature recommendations on the vial or outer packaging.
Keep vials protected from direct light and moisture.
If specified by the supplier, refrigerate or deep-freeze lyophilised peptides to maintain stability; otherwise follow label guidance.
Keep out of reach of unauthorised personnel, children and pets.
Once reconstituted in a research setting, solutions should be handled using appropriate aseptic techniques and discarded in line with institutional policies.